Cargando…

Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease

MAFLD stands for metabolic-related fatty liver disease, which is a prevalent liver disease affecting one-third of adults worldwide, and is strongly associated with obesity, hyperlipidemia, and type 2 diabetes. It encompasses a broad spectrum of conditions ranging from simple liver fat accumulation t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhen, Ouyang, Hao, Zhu, Junfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289001/
https://www.ncbi.nlm.nih.gov/pubmed/37361209
http://dx.doi.org/10.3389/fphar.2023.1195146
_version_ 1785062191106359296
author Li, Zhen
Ouyang, Hao
Zhu, Junfeng
author_facet Li, Zhen
Ouyang, Hao
Zhu, Junfeng
author_sort Li, Zhen
collection PubMed
description MAFLD stands for metabolic-related fatty liver disease, which is a prevalent liver disease affecting one-third of adults worldwide, and is strongly associated with obesity, hyperlipidemia, and type 2 diabetes. It encompasses a broad spectrum of conditions ranging from simple liver fat accumulation to advanced stages like chronic inflammation, tissue damage, fibrosis, cirrhosis, and even hepatocellular carcinoma. With limited approved drugs for MAFLD, identifying promising drug targets and developing effective treatment strategies is essential. The liver plays a critical role in regulating human immunity, and enriching innate and adaptive immune cells in the liver can significantly improve the pathological state of MAFLD. In the modern era of drug discovery, there is increasing evidence that traditional Chinese medicine prescriptions, natural products and herb components can effectively treat MAFLD. Our study aims to review the current evidence supporting the potential benefits of such treatments, specifically targeting immune cells that are responsible for the pathogenesis of MAFLD. By providing new insights into the development of traditional drugs for the treatment of MAFLD, our findings may pave the way for more effective and targeted therapeutic approaches.
format Online
Article
Text
id pubmed-10289001
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102890012023-06-24 Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease Li, Zhen Ouyang, Hao Zhu, Junfeng Front Pharmacol Pharmacology MAFLD stands for metabolic-related fatty liver disease, which is a prevalent liver disease affecting one-third of adults worldwide, and is strongly associated with obesity, hyperlipidemia, and type 2 diabetes. It encompasses a broad spectrum of conditions ranging from simple liver fat accumulation to advanced stages like chronic inflammation, tissue damage, fibrosis, cirrhosis, and even hepatocellular carcinoma. With limited approved drugs for MAFLD, identifying promising drug targets and developing effective treatment strategies is essential. The liver plays a critical role in regulating human immunity, and enriching innate and adaptive immune cells in the liver can significantly improve the pathological state of MAFLD. In the modern era of drug discovery, there is increasing evidence that traditional Chinese medicine prescriptions, natural products and herb components can effectively treat MAFLD. Our study aims to review the current evidence supporting the potential benefits of such treatments, specifically targeting immune cells that are responsible for the pathogenesis of MAFLD. By providing new insights into the development of traditional drugs for the treatment of MAFLD, our findings may pave the way for more effective and targeted therapeutic approaches. Frontiers Media S.A. 2023-06-09 /pmc/articles/PMC10289001/ /pubmed/37361209 http://dx.doi.org/10.3389/fphar.2023.1195146 Text en Copyright © 2023 Li, Ouyang and Zhu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Zhen
Ouyang, Hao
Zhu, Junfeng
Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease
title Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease
title_full Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease
title_fullStr Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease
title_full_unstemmed Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease
title_short Traditional Chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease
title_sort traditional chinese medicines and natural products targeting immune cells in the treatment of metabolic-related fatty liver disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289001/
https://www.ncbi.nlm.nih.gov/pubmed/37361209
http://dx.doi.org/10.3389/fphar.2023.1195146
work_keys_str_mv AT lizhen traditionalchinesemedicinesandnaturalproductstargetingimmunecellsinthetreatmentofmetabolicrelatedfattyliverdisease
AT ouyanghao traditionalchinesemedicinesandnaturalproductstargetingimmunecellsinthetreatmentofmetabolicrelatedfattyliverdisease
AT zhujunfeng traditionalchinesemedicinesandnaturalproductstargetingimmunecellsinthetreatmentofmetabolicrelatedfattyliverdisease